17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website. 18 October 2024
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Anglo-Irish firm Poolbeg Pharma has announced that a number of new investors have expressed interest in acquiring up to £1.6 million ($2.1 million) in shares of the company which are currently locked-up and held in trust by Croft Nominees as a result of the distribution in specie from Open Orphan. 13 April 2022
The Delhi High Court has issued a permanent injunction against two Indian companies protesting Novartis patent for eltrombopag olamine, an active pharmaceutical ingredient in its brand Revolade, till May 21, 2023. 13 April 2022
The European Commission welcomes the swift adoption by the Council of the proposals to ensure the continued long-term supply of medicines from Great Britain to Northern Ireland and to address outstanding supply concerns in Cyprus, Ireland and Malta – markets that have been historically supplied through or by Great Britain. 13 April 2022
The UK is set to become the first country to pay pharmaceutical companies a fixed fee for supplying antibiotics in an effort to tackle the growing global crisis over resistance to the drugs, according to a draft guidance published today by health technology assessor the National Institute of Health and Care Excellence (NICE). 12 April 2022
The new pledge from member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA) should drastically increase the availability of innovative medicines in EU countries and decrease the time patients must wait for new medicines by several months. 12 April 2022
Miami-based Veru has announced positive efficacy and safety results from a planned interim analysis of the Phase III COVID-19 trial evaluating oral sabizabulin 9mg versus placebo in 150 hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS). 11 April 2022
Lundbeck recently completed a global Phase IV, randomized, comparative study exploring the role of vortioxetine as a treatment option between SSRIs and serotonin–noradrenaline reuptake inhibitors (SNRIs), the Danish CNS specialist announced today. 11 April 2022
Danish CNS specialist Lundbeck said on Friday it has has appointed Joerg Hornstein as chief financial officer (CFO) and member of its executive management. He will assume the role no later than September 1, 2022, and he will be registered with the Danish Business Authority. 11 April 2022
A Feature on the Japanese pharma market from Patrick Branch, a Partner in LEK's Tokyo office and a member of the firm’s Life Sciences practice. 8 April 2022
The European pharma industry has commissioned a report on drug affordability which highlights its message that overall expenditure on therapies has remained stable. 7 April 2022
The Russian Ministry of Health has prepared a list of 39 anticancer drugs that are likely to be in short supply in the country due to ongoing military conflict between Ukraine and Russia and Western sanctions imposed on Russia, reports The Pharma Letter’s local correspondent. 7 April 2022
Shares of Texas, USA-based vaccines developer Vaxxinity were up more than 3% to $4.49 pre-market today, as it revealed that the Coalition for Epidemic Preparedness Innovations (CEPI) will co-fund the ongoing global pivotal Phase III clinical trial of Vaxxinity's next generation UB-612 COVID-19 vaccine candidate as a heterologous - or 'mix-and-match' - booster dose. 7 April 2022
French firm Abionyx Pharma has reported positive interim results from an open-label Phase IIa trial of its acute kidney injury (AKI) candidate CER-001. 7 April 2022
US company Citius Pharmaceuticals today reported top-line results from the pivotal Phase III trial of I/ONTAK (E7777; denileukin diftitox)), an engineered interleukin (IL)-2-diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL). 6 April 2022
The US Food and Drug Administration has just approved Igalmi (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia and bipolar I or II disorders in adults. The drug was developed by Connecticut, USA company BioXcel Therapeutics. 6 April 2022
Privately-held German drugmaker Boehringer Ingelheim is always the last pharma major to present its annual financial results, and this year’s results have been worth the wait. 6 April 2022
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.